WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) [...] Read more »
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reported [...] Read more »
Fortrea kündigt KI-gestützte Partnerschaft mit Medidata zur Erhöhung der Diversität in klinischen Studien an
DURHAM, North Carolina, Nov. 20, 2023 (GLOBE NEWSWIRE) — Read more »
Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) — Read more »
Fortrea annonce un partenariat avec Medidata basé sur l’IA afin d’accroître la diversité dans les essais cliniques
DURHAM, Caroline du Nord, 20 nov. 2023 (GLOBE NEWSWIRE) — Read more »
Fortrea Anuncia Parceria Baseada em IA com a Medidata para Aumentar a Diversidade dos Ensaios Clínicos
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) — A Read more »
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reports [...] Read more »
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with their collaborators [...] Read more »
Fortrea schließt Ausbau der klinischen Pharmakologielösungen nach gezielten Investitionen in seine vier klinischen Forschungseinheiten in den USA und im Vereinigten Königreich ab
DURHAM, North Carolina, Nov. 03, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (das "Unternehmen"), ein weltweit fhrendes Auftragsforschungsinstitut (Contract Research Organization, CRO), hat heute bekanntgegeben, dass es [...] Read more »
Fortrea Conclui Expansão das Soluções de Farmacologia Clínica Seguindo Investimentos Direcionados às suas Quatro Unidades de Pesquisa Clínica nos EUA e Reino Unido
DURHAM, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE) (a "Empresa"), uma organizao lder global de pesquisa por contrato (CRO), anunciou hoje que concluiu um trabalho de vrios anos de expanso das suas [...] Read more »
Fortrea achève l’agrandissement de ses solutions de pharmacologie clinique à la suite d’investissements ciblés au sein de ses quatre unités de recherche clinique aux États-Unis et au Royaume-Uni
DURHAM, Caroline du Nord, 03 nov. 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE) (la Socit ), une socit de recherche sous contrat (contract research organization, CRO) internationale de premier plan, a annonc ce jour avoir achev [...] Read more »
Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.
DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it has completed a multi–year effort to [...] Read more »
MeMed awarded US BARDA contract to demonstrate clinical utility of the FDA-cleared MeMed BV® test for distinguishing bacterial from viral infections
Contract awarded under the BARDA DRIVe (Division of Research, Innovation, and Ventures) initiative to harness a patient's systemic response to inform on health threats and clinical impact
Read more »
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received [...] Read more »